Telix Pharmaceuticals Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance
Telix Pharmaceuticals reported group revenue growth of 19% for the quarter ended September 30, 2026, and reaffirmed its full-year 2026 revenue guidance.
CANBERA (dpa-AFX) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.Telix Pharmaceutica…